Background and Objectives
We conducted a multicenter observational study in Germany. Ophthalmologists in outpatient practices and hospital eye clinics consecutively enrolled patients who had already received at least one intravitreal injection. Patients were expected to remain in the study for a minimum follow-up observational period of 12 months. Our DCE was performed in two stages: first, in a qualitative pre-study based on 15 patients, we developed the DCE questionnaire which was then tested for feasibility in a small group. In a second step, we conducted our main quantitative study to investigate patient preferences. Preference interviews were conducted by means of structured telephone interviews. Attributes describing real-world intravitreal injection treatment of nAMD included in the DCE were treatment scheme (fixed appointments every 4 versus 8 weeks versus pro re nata), change of visual acuity (VA) in the next 12 months (stability versus improvement versus worsening), and the time the patient needs for each eye doctor visit (3 versus 6 versus 9 hours). Selected data were modelled using a random utility maximization framework [5, 6] . Specifically, in a conditional logit regression model, the influence of different attribute levels on the probability of a patient deciding to choose a specific treatment option were estimated. In an additional analysis, estimated marginal utilities for each attribute level were used to quantify the relative importance of each attribute in the patient's decision for or against a treatment option. Both analyses were performed for the whole sample and for separate subgroups as defined by age, gender, baseline VA, and potential need for any help in daily life. Finally, marginal willingness to accept an additional hour of waiting/treatment/travel time per eye specialist visit to receive a specific treatment with a more favorable attribute level was calculated based on the whole sample. All analyses were performed using IBM SPSS 20.0 software.
Methods

Study sample
284 patients were included in the analysis (mean age 77.4, 59.9% female). At study inclusion, 22.9% had severe visual impairment, 54.9% had moderate and 14.1% had mild visual impairment; for 8.1% of the patients, baseline data about VA were not available (Table 1) .
Patient preferences based on the DCE
In the overall group, the influence of selected attributes on preferences was statistically significant for two of the three attributes. Generally, patients preferred the attribute levels 'improvement in VA' and 'less waiting, treatment and travel time'. The results for the attribute 'treatment scheme' were inconclusive; none of the attribute levels were associated with statistically significant utility differences ( Table 2 ). Our subgroup analyses showed similar results as for the whole sample. In terms of preferences for different treatment schemes, however, women and patients with a moderate baseline VA expected more benefit from injections every 4 weeks than from a PRN scheme. Utility differences between injections every 8 weeks and a PRN regime were not statistically significant. The attribute with the highest impact on patient preferences was 'change of VA' which influenced overall decisions for or against a treatment option in 73.6% of cases (70.3-75.2% in the respective subsamples). The attribute with the second highest importance was 'waiting, treatment and travel time', influencing overall decisions in 21.0% of cases (19.0-23.5% in the respective subsamples). The attribute with the lowest weighting was 'treatment scheme', influencing overall decisions in 5.4% of cases (3.9-9.5% in the respective subsamples) (Figure 1 ).
Utility analyses
Negative coefficients (Table 2) indicating lower utility associated with a longer waiting, treatment and travel time for each physician consultation were able to be expressed in terms of the patient's "willingness" to accept an additional waiting and travelling time for better VA.
Patients stated to be willing to accept an additional time spent for each physician visit of 12.7 hours to achieve stable VA rather than worse VA. To obtain improved VA, patients stated to be willing to accept an additional time spent per physician visit of 21.2 hours (8.5 hours for a worsening in VA or stable VA).
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Limitations
We acknowledge some limitations of this study. First, despite random selection of study centers and consecutive inclusion of patients, there may have been selection bias on the part of the physicians and patients. Second, we were able to conduct interviews in only 83.4% of initially enrolled patients resulting in possible response bias. This is partially relativized by the similarity of the patient characteristics of included and excluded patients. A further limitation is that we included only nAMD patients experienced in intravitreal injection therapy, mostly based on a PRN scheme. This might have biased patients' voting for fixed injections every 4 weeks or the PRN scheme. Finally, the alternative attributes we chose describe available treatment options in only very general and simplified terms because, as one of the major methodological limitations of DCEs , the number of attributes or attribute levels that can be presented to patients is limited.
Conclusions and implications for practice
Neovascular age-related macular degeneration patients expressed a strong preference for intravitreal treatment schemes associated with the highest degree of VA that can be achieved, even if these involve a high treatment burden. Less rigid and less effective PRN schemes which are most frequently used in the everyday clinical setting do not meet patients' expectations.
Discussion
Results
Patients with nAMD prefer a treatment scheme associated with an improvement in VA, even if it is associated with a high treatment burden. This result also indicates that patients are willing to accept a high treatment burden for the management of their disease. The results of our DCE do not confirm the hypothesis that treatment schemes such as a PRN or schemes associated with less frequent injections and eye exams may be preferred by patients. So, a potential undertreatment of nAMD patients as observed in real-world studies is probably not be related to nAMD patient preferences towards a lower treatment burden. 
